000			02982nam a22003855i 4500
001			76323
003			ES-MaUEC
005			20230207040219.0
007			cr nn 008mamaa
008			100301s2006 gw | s |||| 0|eng d
020			_a9783540298021
024	7		_a10.1007/3-540-29802-9 _2doi
040			_aES-MaUEC
050		4	_aRC848.H42 _bH47 2006 EB
082	0	4	_a616.9101
245	0	0	_aHepatitis Delta Virus _cedited by John L. Casey
260			_aBerlin, Heidelberg _bSpringer International Publishing _c2006
300			_a1 recurso en línea (XI, 228 p.) _b25 ilustraciones
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aCurrent Topics in Microbiology and Immunology _x0070-217X _v307
505	0		_aStructure and Replication of Hepatitis Delta Virus RNA -- HDV RNA Replication: Ancient Relic or Primer? -- HDV Ribozymes -- RNA Editing in Hepatitis Delta Virus -- Post-translational Modification of Delta Antigen of Hepatitis D Virus -- The Role of the HBV Envelope Proteins in the HDV Replication Cycle -- Prenylation of HDAg and Antiviral Drug Development -- Hepatitis Delta Virus Genetic Variability: From Genotypes I, II, III to Eight Major Clades? -- Functional and Clinical Significance of Hepatitis D Virus Genotype II Infection -- Immunology of HDV Infection -- The Woodchuck Model of HDV Infection
520			_aSince its discovery nearly 30 years ago, hepatitis delta virus (HDV) has continued to surprise and fascinate. At 1,680 nucleotides the HDV genome is the smallest known to infect man. It is unique among animal viruses, the closest known relatives being plant viroids. To compensate for its limited protein coding capacity, HDV relies heavily on host functions and on structural features of its circular RNA genome. HDV infection depends on hepatitis B virus as a helper, and increases the severity of liver disease caused by HBV alone. There is currently neither an effective HDV vaccine nor a generally accepted useful therapy for HDV infection. This volume encompasses recent developments in HDV research, from molecular virology to genetics to experimental investigation of new therapeutic and vaccine candidates
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aHepatitis _9142760 _0comprobar BNE19901024018 _2embne
650		7	_aVirología _0comprobar BNE19900995429 _2embne _9413113
700	1		_aCasey, John L. _eeditor literario _985327 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/3-540-29802-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783540298021
907			_a.b12819414 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b15-07-17 _cm _dz _eu _feng _ggw _h0
945			_aRC848 .H42 H47 2006 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11548630 _z06-04-17
999			_c76323 _d76323 _x1